258 related articles for article (PubMed ID: 22064453)
1. Controlled release of insulin from self-assembling nanofiber hydrogel, PuraMatrix™: application for the subcutaneous injection in rats.
Nishimura A; Hayakawa T; Yamamoto Y; Hamori M; Tabata K; Seto K; Shibata N
Eur J Pharm Sci; 2012 Jan; 45(1-2):1-7. PubMed ID: 22064453
[TBL] [Abstract][Full Text] [Related]
2. Potential use of gamma-cyclodextrin polypseudorotaxane hydrogels as an injectable sustained release system for insulin.
Abu Hashim II; Higashi T; Anno T; Motoyama K; Abd-ElGawad AE; El-Shabouri MH; Borg TM; Arima H
Int J Pharm; 2010 Jun; 392(1-2):83-91. PubMed ID: 20298768
[TBL] [Abstract][Full Text] [Related]
3. Controlled release of insulin from pH/temperature-sensitive injectable pentablock copolymer hydrogel.
Huynh DP; Im GJ; Chae SY; Lee KC; Lee DS
J Control Release; 2009 Jul; 137(1):20-4. PubMed ID: 19285530
[TBL] [Abstract][Full Text] [Related]
4. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin.
Zhang Y; Wei W; Lv P; Wang L; Ma G
Eur J Pharm Biopharm; 2011 Jan; 77(1):11-9. PubMed ID: 20933083
[TBL] [Abstract][Full Text] [Related]
5. Two-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies.
Koutsopoulos S; Zhang S
J Control Release; 2012 Jun; 160(3):451-8. PubMed ID: 22465676
[TBL] [Abstract][Full Text] [Related]
6. Functionalized injectable hydrogels for controlled insulin delivery.
Huynh DP; Nguyen MK; Pi BS; Kim MS; Chae SY; Lee KC; Kim BS; Kim SW; Lee DS
Biomaterials; 2008 Jun; 29(16):2527-34. PubMed ID: 18329707
[TBL] [Abstract][Full Text] [Related]
7. The development and characteristics of novel microneedle arrays fabricated from hyaluronic acid, and their application in the transdermal delivery of insulin.
Liu S; Jin MN; Quan YS; Kamiyama F; Katsumi H; Sakane T; Yamamoto A
J Control Release; 2012 Aug; 161(3):933-41. PubMed ID: 22634072
[TBL] [Abstract][Full Text] [Related]
8. Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin.
Uehata K; Anno T; Hayashida K; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
Int J Pharm; 2012 Jan; 422(1-2):33-9. PubMed ID: 22020273
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, and in vivo evaluation of insulin-loaded PLA-PEG microspheres for controlled parenteral drug delivery.
Sheshala R; Peh KK; Darwis Y
Drug Dev Ind Pharm; 2009 Nov; 35(11):1364-74. PubMed ID: 19832637
[TBL] [Abstract][Full Text] [Related]
10. Novel lyophilized hydrogel patches for convenient and effective administration of microneedle-mediated insulin delivery.
Qiu Y; Qin G; Zhang S; Wu Y; Xu B; Gao Y
Int J Pharm; 2012 Nov; 437(1-2):51-6. PubMed ID: 22842625
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of in situ gel system for nasal insulin delivery.
Agrawal AK; Gupta PN; Khanna A; Sharma RK; Chandrawanshi HK; Gupta N; Patil UK; Yadav SK
Pharmazie; 2010 Mar; 65(3):188-93. PubMed ID: 20383938
[TBL] [Abstract][Full Text] [Related]
12. Injectable and biodegradable thermosensitive hydrogels loaded with PHBHHx nanoparticles for the sustained and controlled release of insulin.
Peng Q; Sun X; Gong T; Wu CY; Zhang T; Tan J; Zhang ZR
Acta Biomater; 2013 Feb; 9(2):5063-9. PubMed ID: 23036950
[TBL] [Abstract][Full Text] [Related]
13. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment.
Wan CK; Giacca A; Matsuhisa M; El-Bahrani B; Lam L; Rodgers C; Shi ZQ
Metabolism; 2000 Aug; 49(8):984-9. PubMed ID: 10954014
[TBL] [Abstract][Full Text] [Related]
14. Controlled delivery of basal insulin from phase-sensitive polymeric systems after subcutaneous administration: in vitro release, stability, biocompatibility, in vivo absorption, and bioactivity of insulin.
Al-Tahami K; Oak M; Singh J
J Pharm Sci; 2011 Jun; 100(6):2161-71. PubMed ID: 21491440
[TBL] [Abstract][Full Text] [Related]
15. Oral insulin delivery using P(MAA-g-EG) hydrogels: effects of network morphology on insulin delivery characteristics.
Nakamura K; Murray RJ; Joseph JI; Peppas NA; Morishita M; Lowman AM
J Control Release; 2004 Mar; 95(3):589-99. PubMed ID: 15023469
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
[TBL] [Abstract][Full Text] [Related]
17. Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats.
Uehata K; Anno T; Hayashida K; Motoyama K; Hirayama F; Ono N; Pipkin JD; Uekama K; Arima H
Int J Pharm; 2011 Oct; 419(1-2):71-6. PubMed ID: 21803140
[TBL] [Abstract][Full Text] [Related]
18. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery.
Makhlof A; Tozuka Y; Takeuchi H
Eur J Pharm Sci; 2011 Apr; 42(5):445-51. PubMed ID: 21182939
[TBL] [Abstract][Full Text] [Related]
19. Self-nanoemulsifying drug delivery systems for oral insulin delivery: in vitro and in vivo evaluations of enteric coating and drug loading.
Li P; Tan A; Prestidge CA; Nielsen HM; Müllertz A
Int J Pharm; 2014 Dec; 477(1-2):390-8. PubMed ID: 25455781
[TBL] [Abstract][Full Text] [Related]
20. [Studies on the insulin-liposomes double-coated by chitosan and chitosan-EDTA conjugates].
Wu ZH; Ping QN; Song YM; Lei XM; Li JY; Cai P
Yao Xue Xue Bao; 2004 Nov; 39(11):933-8. PubMed ID: 15696937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
